Rapid detection of infection is essential for stopping the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Roche SD Biosensor rapid antigen test for SARS-CoV-2 was evaluated in a nonhospitalized symptomatic population. We rapid-tested a sample onsite and compared results with those from reverse transcription PCR and virus culture. We analyzed date of onset and symptoms using data from a clinical questionnaire. Overall test sensitivity was 84.9% (95% CI 79.1–89.4) and specificity was 99.5% (95% CI 98.7–99.8). Sensitivity increased to 95.8% (95% CI 90.5–98.2) for persons who sought care within 7 days of symptom onset. Test band intensity and time to result correlated strongly with viral load; thus, strong positive results could be read before the recommended time. Approximately 98% of all viable specimens with cycle threshold <30 were detected. Rapid antigen tests can detect symptomatic SARS-CoV-2 infections in the early phase of disease, thereby identifying the most infectious persons.
【저자키워드】 COVID-19, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, SARS-CoV-2, diagnostics, rapid antigen test, clinical evaluation, The Netherlands, Roche, 【초록키워드】 coronavirus, Infection, Test, Symptom, severe acute respiratory syndrome Coronavirus, virus, Antigen, Spread, sensitivity, specificity, Rapid antigen tests, Viral, Culture, Viral load, cycle threshold, symptomatic, Rapid, virus culture, respiratory, reverse transcription PCR, disease, Care, SARS-CoV-2 infections, date of onset, symptom onset, intensity, acute respiratory syndrome, 95% CI, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, positive result, early phase, specimen, SD Biosensor, symptomatic SARS-CoV-2 infection, clinical questionnaire, analyzed, detect, evaluated, correlated strongly, 【제목키워드】 Test, Testing, clinical, Rapid, service, SD Biosensor, Netherland, Site,